文献速递神经肿瘤

EGFR通过促进p53与DNA-PKcs结合抑制p53功能:胶质母细胞瘤中EGFR与野生型p53之间的非经典调控轴

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
PubMed 文献 · Neuro Oncol · 2022-01-01

研究在胶质母细胞瘤中探讨EGFR扩增与野生型p53功能的关系,用质谱、免疫共沉淀和CRISPR-Cas9等技术发现DNA-PKcs是p53相互作用蛋白并抑制p53活性,EGFR敲低增加野生型p53转录活性且与p53-DNA-PKcs结合减少相关,抑制DNA-PKcs后EGFR敲低不再进一步增强p53活性,条件性敲除EGFR可延长移植野生型p53胶质瘤球形成细胞小鼠的生存。

要点

  • DNA-PKcs被鉴定为功能性抑制p53活性的p53相互作用蛋白。
  • EGFR敲低增加野生型p53转录活性,伴p53与DNA-PKcs结合减少。
  • 抑制DNA-PKcs后EGFR敲低不再进一步增强p53活性,条件性敲除EGFR延长小鼠生存。

核心结论

  • 本研究证明EGFR信号通过促进p53与DNA-PKcs相互作用来抑制胶质母细胞瘤中野生型p53的功能。

研究设计与样本

  • 采用质谱鉴定EGFR依赖的p53相互作用蛋白,用免疫共沉淀检测p53与DNA-PKcs结合。
  • 用CRISPR-Cas9基因编辑敲除EGFR和DNA-PKcs,用Edit-R CRISPR-Cas9系统条件性敲除EGFR。
  • 用CM-H2DCFDA探针测ROS活性,用实时PCR定量p53靶基因表达,并使用胶质瘤球形成细胞(GSCs)。

主要发现

  • 在胶质瘤球形成细胞中鉴定DNA-PKcs为功能性抑制p53活性的p53相互作用蛋白。
  • EGFR敲低增加野生型p53转录活性,并与p53与DNA-PKcs结合减少相关。
  • 用siRNA或抑制剂nedisertib抑制DNA-PKcs增加野生型p53转录活性,且EGFR敲低未进一步增强该活性。
  • 条件性敲除EGFR的GSCs移植小鼠中,耗尽EGFR增加动物生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidermal growth factor receptor (EGFR) amplification and TP53 mutation are the two most common genetic alterations in glioblastoma multiforme (GBM). A comprehensive analysis of the TCGA GBM database revealed a subgroup with near mutual exclusivity of EGFR amplification and TP53 mutations indicative of a role of EGFR in regulating wild-type-p53 (wt-p53) function. The relationship between EGFR amplification and wt-p53 function remains undefined and this study describes the biological significance of this interaction in GBM. METHODS: Mass spectrometry was used to identify EGFR-dependent p53-interacting proteins. The p53 and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) interaction was detected by co-immunoprecipitation. We used CRISPR-Cas9 gene editing to knockout EGFR and DNA-PKcs and the Edit-R CRIPSR-Cas9 system for conditional knockout of EGFR. ROS activity was measured with a CM-H2DCFDA probe, and real-time PCR was used to quantify expression of p53 target genes. RESULTS: Using glioma sphere-forming cells (GSCs), we identified, DNA-PKcs as a p53 interacting protein that functionally inhibits p53 activity. We demonstrate that EGFR knockdown increased wt-p53 transcriptional activity, which was associated with decreased binding between p53 and DNA-PKcs. We further show that inhibition of DNA-PKcs either by siRNA or an inhibitor (nedisertib) increased wt-p53 transcriptional activity, which was not enhanced further by EGFR knockdown, indicating that EGFR suppressed wt-p53 activity through DNA-PKcs binding with p53. Finally, using conditional EGFR-knockout GSCs, we show that depleting EGFR increased animal survival in mice transplanted with wt-p53 GSCs. CONCLUSION: This study demonstrates that EGFR signaling inhibits wt-p53 function in GBM by promoting an interaction between p53 and DNA-PKcs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ding J, Li X, Khan S, et al. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol. 2022. PMID: 35474131. doi:10.1093/neuonc/noac105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。